INOVIO Pharmaceuticals, Inc., the Plymouth Meeting-based pharmaceutical company, will test the first dose of its COVID-19 vaccine today on a healthy volunteer.
“This is a significant step forward in the global fight against COVID-19,” said Dr. J. Joseph Kim, INOVIO’s president and CEO. “Without a new safe and effective vaccine, the COVID-19 pandemic is likely to continue to threaten lives and livelihoods.”
Inovio has been working on the vaccine since January and is enrolling 40 healthy adult volunteers to test it. One million doses are expected to be available by year-end for additional trials and emergency use, pending appropriate regulatory guidance and funding.
